In response to the recent news article: FDA GIVES PRIORITY REVIEW OF TRUVADA AS PREP
AHF Challenges FDA Move to Fast Track Gileads HIV Prevention Drug
Decision to grant expedited review of drug application comes just days after release of study showing the drug, Truvada, is associated with significant risk of kidney damage and disease that increases over time.
AIDS Healthcare Foundation (AHF), the nation’s largest HIV/AIDS nonprofit medical provider, today expressed its disappointment and dismay at the Food and Drug Administration’s (FDA) decision to grant an expedited review for Gilead Sciences’ application for expanded use of its blockbuster AIDS drug, Truvada, as a means of preventing HIV infection in non-infected people. AHF has long voiced concerns that such a use would actually increase HIV infections, and the announcement comes just days after researchers reported that a component of Truvada (which is a combination containing two Gilead drugs—tenofovir DF + emtricitabine—in one tablet), is linked to a significant risk of kidney disease and damage. Most alarmingly, the risk remains even after people stop taking the drug.